Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
Primary Purpose
Kidney Stones
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Cyberwand
single probe ultrasonic
Sponsored by
About this trial
This is an interventional treatment trial for Kidney Stones focused on measuring Kidney Stones, Renal Calculi
Eligibility Criteria
Inclusion Criteria: Patient of Methodist Urology in Indianapolis, IN Undergoing percutaneous nephrolithotomy for calculi greater than 2 cm Age 18 years or older Stone easily visible/measurable on kidney, ureters and bladder (KUB) or computed tomography (CT) scan preoperatively Exclusion Criteria: Radiolucent stones Size of largest stone less than 2 cm Pregnancy Inability to give informed consent Multiple percutaneous access anticipated Active urinary tract infection Recent (within last 3 months) extracorporeal shock wave lithotripsy
Sites / Locations
- Northwestern University Dept. of Urology
- Methodist Hospital
- John's Hopkins University
- Duke University
- University of Wisconsin
- Vancouver Hospital
- University of Western Ontario - St. Joseph's Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
A
B
Arm Description
Cyberwand
Currently available lithotripsy technology
Outcomes
Primary Outcome Measures
Kidney Stone Clearance Rate
stone clearance rate calculated in mm^2/min per protocol specification
Secondary Outcome Measures
Full Information
NCT ID
NCT00351351
First Posted
July 11, 2006
Last Updated
March 1, 2017
Sponsor
Indiana Kidney Stone Institute
1. Study Identification
Unique Protocol Identification Number
NCT00351351
Brief Title
Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
Official Title
Randomized Control Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
July 2006 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Indiana Kidney Stone Institute
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Percutaneous nephrolithotomy (PNL), in conjunction with intracorporeal lithotripsy, allows for the rapid removal of any kidney stone regardless of size. Currently, the choice of intracorporeal lithotripters includes ultrasonic, pneumatic, and combined ultrasonic/pneumatic energy sources. Recently, a novel dual probe design as been introduced by Cybersonics of Erie, Pennsylvania. This dual probe intracorporeal lithotrite is called the Cyberwand, and is composed of a fixed inner probe vibrating at an ultrasonic frequency with an outer probe vibrating at about 1,000 Hz. As this new design has the potential to revolutionize intracorporeal lithotripsy, we intend to compare this novel technology to currently available lithotripsy technology in a randomized clinical trial.
Detailed Description
Percutaneous nephrolithotomy (PNL) is used to remove large and complex stones from the upper urinary tract. Intracorporeal lithotripsy is an integral part of PNL. Commercially available intracorporeal lithotripsy modalities include ultrasonic, pneumatic, and combined ultrasonic and pneumatic models. Each modality has its inherent advantages and disadvantages. Ultrasonic lithotrites are capable of fragmenting stones while concomitantly suctioning out fragments. Unfortunately some stones are hard enough to resist fragmentation from ultrasonic lithotripsy. Pneumatic lithotrites are able to fragment all stones regardless of hardness, but this modality is unable to suction out stone pieces at the same time fragmentation is occurring. The newest lithotrite which combines both ultrasonic and pneumatic components is capable of fragmenting any stone, but also has some inherent limitations. The handpiece of the lithotripsy device is somewhat cumbersome, the suction component can clog, and the device has overheated at the maximal settings (Kuo et al). Current intracorporeal lithotrites, while functional, can certainly be improved.
Recently, a novel dual probe design has been introduced by Cybersonics of Erie, PA. This dual probe intracorporeal lithotrite is called the Cyberwand and is composed of a fixed inner probe vibrating at an ultrasonic frequency with an outer probe vibrating at about 1,000 Hz. As this new design has the potential to revolutionalize intracorporeal lithotripsy, we intend to compare this novel technology to currently available lithotripsy technology in a randomized clinical trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Stones
Keywords
Kidney Stones, Renal Calculi
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
70 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Description
Cyberwand
Arm Title
B
Arm Type
Active Comparator
Arm Description
Currently available lithotripsy technology
Intervention Type
Device
Intervention Name(s)
Cyberwand
Intervention Description
FDA approved - dual probe intracorporeal lithotrite
Intervention Type
Device
Intervention Name(s)
single probe ultrasonic
Intervention Description
FDA-approved - single probe ultrasonic
Primary Outcome Measure Information:
Title
Kidney Stone Clearance Rate
Description
stone clearance rate calculated in mm^2/min per protocol specification
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient of Methodist Urology in Indianapolis, IN
Undergoing percutaneous nephrolithotomy for calculi greater than 2 cm
Age 18 years or older
Stone easily visible/measurable on kidney, ureters and bladder (KUB) or computed tomography (CT) scan preoperatively
Exclusion Criteria:
Radiolucent stones
Size of largest stone less than 2 cm
Pregnancy
Inability to give informed consent
Multiple percutaneous access anticipated
Active urinary tract infection
Recent (within last 3 months) extracorporeal shock wave lithotripsy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James E. Lingeman, MD
Organizational Affiliation
Methodist Urology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University Dept. of Urology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Methodist Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
John's Hopkins University
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
University of Wisconsin
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Facility Name
Vancouver Hospital
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
University of Western Ontario - St. Joseph's Hospital
City
London
State/Province
Ontario
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
15072622
Citation
Kuo RL, Paterson RF, Siqueira TM Jr, Evan AP, McAteer JA, Williams JC Jr, Lingeman JE. In vitro assessment of lithoclast ultra intracorporeal lithotripter. J Endourol. 2004 Mar;18(2):153-6. doi: 10.1089/089277904322959789.
Results Reference
background
Learn more about this trial
Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
We'll reach out to this number within 24 hrs